Galectin Therapeutics Inc.
GALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2 | $10 | $10 |
| Gross Profit | $0 | -$2 | -$10 | -$10 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,611 | $3,261 | $6,485 | $11,109 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,587 | $1,362 | $1,402 | $1,309 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,198 | $4,623 | $7,887 | $12,418 |
| Operating Income | -$4,198 | -$4,625 | -$7,897 | -$12,428 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3,986 | -$2,896 | -$1,734 | $461 |
| Pre-Tax Income | -$8,184 | -$7,521 | -$9,631 | -$11,967 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,184 | -$7,521 | -$9,631 | -$11,967 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.12 | -0.15 | -0.19 |
| % Growth | -8.3% | 20% | 21.1% | – |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.19 |
| Weighted Avg Shares Out | 64,205 | 63,447 | 63,204 | 62,740 |
| Weighted Avg Shares Out Dil | 64,205 | 63,447 | 63,204 | 62,740 |
| Supplemental Information | – | – | – | – |
| Interest Income | $39 | $26 | $35 | $84 |
| Interest Expense | $1,820 | $1,826 | $1,744 | $1,725 |
| Depreciation & Amortization | $0 | $2 | $10 | $10 |
| EBITDA | -$6,364 | -$5,693 | -$7,877 | -$10,232 |
| % Margin | – | – | – | – |